ApoB, LDL-C, and Non-HDL-C as Markers of Cardiovascular Risk: A Systematic Review of Discordance Analyses

This systematic review compiled all available discordance analyses comparing ApoB and LDL particle number (LDL-P) versus LDL-C and non-HDL-C as cardiovascular risk markers, encompassing 593,354 participants across multiple cohorts.

The results were definitive on ApoB’s superiority over LDL-C: in 9 of 9 studies (100%), ApoB was the superior cardiovascular risk marker when the two were discordant. ApoB was superior to non-HDL-C in 7 of 9 studies (78%). LDL-P was superior to LDL-C in 2 of 3 studies. No study found LDL-C to be superior to ApoB.

The discordance methodology is the appropriate test of a marker’s independent value: when ApoB and LDL-C rank patients differently, which ranking better predicts future events? This question answers directly whether ApoB provides unique cardiovascular risk information beyond what LDL-C captures. The 100% consistency across 9 independent studies eliminates concern that any individual study’s result was idiosyncratic.

The clinical conclusion the authors draw — that ApoB should be the primary measure for estimating cardiovascular risk and assessing adequacy of lipid-lowering therapy — is the most explicit evidence-based statement in the literature for replacing LDL-C with ApoB as the primary lipid parameter in clinical practice.

We rate the evidence strong. The most comprehensive systematic review of ApoB/LDL-C discordance analyses, unanimously confirming ApoB’s superiority — the definitive review supporting a paradigm shift from LDL-C to ApoB in cardiovascular risk assessment.